Summary of urothelial carcinoma clinical studies with high-sensitivity plasma ctDNA.
| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Christensen | 2019 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 68 | 100% | 98% | 129.6 | 13.7 weeks | Christenson12 |
| Powles | 2021 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 581 | 59% | 99.8% | 0.58 | NR | Powles13 |
| Young | 2024 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 40 | NR | NR | NR | NR | Young15 |
| Kommalapati | 2023 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 109 | 94% | NR | 9.9 | 61 days | Kommalapati16 |
| Carrasco | 2022 | Agnostic ddPCR | MIBC | 37 | NR | NR | 4.199 | NR | Carrasco18 |
| van Dorp | 2023 | Bespoke PCR (RaDaR) | MIBC | 17 | NR | 100% | 10.4 | NR | van Dorp, 202321 |
| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Christensen | 2019 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 68 | 100% | 98% | 129.6 | 13.7 weeks | Christenson12 |
| Powles | 2021 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 581 | 59% | 99.8% | 0.58 | NR | Powles13 |
| Young | 2024 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 40 | NR | NR | NR | NR | Young15 |
| Kommalapati | 2023 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 109 | 94% | NR | 9.9 | 61 days | Kommalapati16 |
| Carrasco | 2022 | Agnostic ddPCR | MIBC | 37 | NR | NR | 4.199 | NR | Carrasco18 |
| van Dorp | 2023 | Bespoke PCR (RaDaR) | MIBC | 17 | NR | 100% | 10.4 | NR | van Dorp, 202321 |
Abbreviations: MIBC, muscle-invasive bladder cancer, NR, not reported.
Summary of urothelial carcinoma clinical studies with high-sensitivity plasma ctDNA.
| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Christensen | 2019 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 68 | 100% | 98% | 129.6 | 13.7 weeks | Christenson12 |
| Powles | 2021 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 581 | 59% | 99.8% | 0.58 | NR | Powles13 |
| Young | 2024 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 40 | NR | NR | NR | NR | Young15 |
| Kommalapati | 2023 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 109 | 94% | NR | 9.9 | 61 days | Kommalapati16 |
| Carrasco | 2022 | Agnostic ddPCR | MIBC | 37 | NR | NR | 4.199 | NR | Carrasco18 |
| van Dorp | 2023 | Bespoke PCR (RaDaR) | MIBC | 17 | NR | 100% | 10.4 | NR | van Dorp, 202321 |
| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Christensen | 2019 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 68 | 100% | 98% | 129.6 | 13.7 weeks | Christenson12 |
| Powles | 2021 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 581 | 59% | 99.8% | 0.58 | NR | Powles13 |
| Young | 2024 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 40 | NR | NR | NR | NR | Young15 |
| Kommalapati | 2023 | Bespoke PCR (Signatera, Natera Inc.) | MIBC | 109 | 94% | NR | 9.9 | 61 days | Kommalapati16 |
| Carrasco | 2022 | Agnostic ddPCR | MIBC | 37 | NR | NR | 4.199 | NR | Carrasco18 |
| van Dorp | 2023 | Bespoke PCR (RaDaR) | MIBC | 17 | NR | 100% | 10.4 | NR | van Dorp, 202321 |
Abbreviations: MIBC, muscle-invasive bladder cancer, NR, not reported.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
